Efficacy of Humanized Cefiderocol Exposure is Unaltered by Host Iron Overload in the Thigh Infection Model.
Cefiderocol is a siderophore-cephalosporin conjugate with greater in vitro potency in iron-depleted conditions. During infection, iron is scarce in host tissue, however, it is not known whether iron overload in the host, such as in cases of hereditary hemochromatosis, alters the efficacy of cefiderocol. We compared cefiderocol efficacy between iron overloaded and standard murine thigh infection models.Female CD-1 mice rendered neutropenic received two weeks of iron dextran 100 mg/kg/d intraperitoneally (iron overloaded model) or no injections (standard model). Mice were inoculated (107 CFU/mL) with Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa with previously determined cefiderocol MIC from 0.25 to 64 mg/L. Human-simulated regimens of cefiderocol or meropenem (2g q8h, 3-h infusion) were administered for 24 h (31 strains) or 72 h (15 strains; cefiderocol only). Procedures were simultaneously performed in standard and iron overloaded models.Mean bacterial burdens (log10 CFU/thigh) at baseline were 5.75±0.47 v. 5.81±0.51 in standard v. iron overloaded models, respectively. At 24 h, mean burdens in standard v. iron overloaded models decreased by -0.8±1.9 v. -1.2±2.0 (p=0.25) in meropenem-treated mice and by -1.5±1.4 v. -1.6±1.5 (p=0.54) in cefiderocol-treated mice. At 72 h, mean burdens in cefiderocol-treated mice decreased by -2.5±1.5 v. -2.5±1.4. No overall differences in efficacy between the models were observed for meropenem or cefiderocol.Human-simulated exposure of cefiderocol is equally efficacious in iron overloaded and normal hosts. The potential clinical use of cefiderocol to treat Gram-negative infections in patients with iron overload is supported.